CENCORA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.7 USD | -1.95% |
|
-6.26% | +9.43% |
| May. 02 | UBS Adjusts Price Target on Cencora to $275 From $277, Maintains Buy Rating | MT |
| May. 02 | TD Cowen Adjusts Price Target on Cencora to $265 From $261 | MT |
Financials (USD)
| Sales 2024 * | 291B | Sales 2025 * | 311B | Capitalization | 45.71B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.04B | Net income 2025 * | 2.33B | EV / Sales 2024 * | 0.16 x |
| Net Debt 2024 * | 1.01B | Net cash position 2025 * | 1.57B | EV / Sales 2025 * | 0.14 x |
| P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
18.8
x | Employees | 46,000 |
| Yield 2024 * |
0.92% | Yield 2025 * |
0.94% | Free-Float | 58.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cencora, Inc.
More recommendations
More press releases
More news
| 1 day | -1.95% | ||
| 1 week | -6.26% | ||
| Current month | -5.99% | ||
| 1 month | -7.55% | ||
| 3 months | -4.36% | ||
| 6 months | +16.94% | ||
| Current year | +9.43% |
1 week
224.32
240.86
1 month
224.32246.65
Current year
204.53246.75
1 year
163.37246.75
3 years
111.34246.75
5 years
72.06246.75
10 years
63.88246.75
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Collis
CEO | Chief Executive Officer | 62 | 93-12-31 |
James Cleary
DFI | Director of Finance/CFO | 61 | 15-01-31 |
Jennifer Dubas
CMP | Compliance Officer | - | 22-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kathleen Hyle
BRD | Director/Board Member | 65 | 10-05-12 |
| Director/Board Member | 74 | 08-09-24 | |
D. Mark Durcan
BRD | Director/Board Member | 62 | 15-09-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.85% | 2 M€ | +21.73% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 224.7 | -1.95% | 2,042,113 |
| 24-05-01 | 229.2 | -4.12% | 3,291,636 |
| 24-04-30 | 239 | -0.37% | 1,589,325 |
| 24-04-29 | 239.9 | -0.39% | 912,088 |
| 24-04-26 | 240.9 | +0.47% | 972,783 |
Delayed Quote Nyse, May 02, 2024 at 04:00 pm EDT
More quotes
Cencora, Inc. specializes in distributing pharmaceutical products. The group supplies generic and name-brand medications, OTC healthcare products, and home care equipment to healthcare providers (hospitals, clinics, pharmacies, physicians, etc.) located in the United States and Canada. The group also offers services to physicians and patients (support and reimbursement assistance services, prescription management services, nursing services, home injection and perfusion services, etc.).
Calendar
2024-07-30
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
224.7
USD
Average target price
254.5
USD
Spread / Average Target
+13.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.43% | 45.67B | |
| -3.77% | 184B | |
| -1.77% | 107B | |
| -1.43% | 67.52B | |
| +2.06% | 50.06B | |
| +3.40% | 41B | |
| +3.04% | 26.73B | |
| +4.64% | 26.47B | |
| +15.23% | 25.05B | |
| -2.66% | 24.56B |
- Stock Market
- Equities
- COR Stock
